Official US documents have disclosed that a popular anti-stroke medicine may have used fictitious data while concealing research on its fatal effects. In 2009, the acclaimed British medical journal, The Lancet, published a prime story on rivaroxaban, a blood thinner medicine, which showed that the treatment was safe and efficient. But recently, the same journal warned of defaults in the trial data and claimed to initiate an investigation over it.

Lancet opens probe into ‘unreliable’ anti-stroke medicine

lancet-lab

Lancet Lab, News on Lancet Lab, stories on Lancet Lab, articles on Lancet Lab, Lancet Lab stories at Wion, Lancet Lab news, Lancet Lab latest news

lancet lab

Lancet opens probe into ‘unreliable’ anti-stroke medicine